These include mono agonists, glucagonlike peptide-1 receptor agonists (GLP-1 agonists), and dual agonists that combine a glucose-dependent insulinotropic polypeptide (GIP) with a GLP-1 agonist (GIP/GLP-1), which have demonstrated a 15% and greater weight loss in people with obesity and/or type 2 diabetes, says Richard E
In 2023, the market was valued at approximately US $3.6 billion, and it is projected to reach $6.2 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 8% during the forecast period (20242030) [8]
Support your nutritional needs by using Herbalifes GLP-1 Companion Pack. Then theres Conagra Brands the company behind brands like Birds Eye, Gardein, Chef Boyardee and Mrs
10.1007/s00213-014-3687-y Psychopharmacology 31 Gonzlez RamrezM
In regards to the current GLP-1 medication shortage, Cutler said this is a topic and a struggle he deals with on a daily basis